All Oncology News

The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.

Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.

The EMA’s CHMP has issued a positive opinion for UM171 cell therapy for patients with hematological malignancies and limited stem cell transplant options.

The European Medicines Agency’s CHMP has recommended the approval of darolutamide plus ADT in mHSPC in the European Union.

The EMA’s Committee for Medicinal Products for Human Use granted a positive opinion for nirogacestat for the treatment of patients with desmoid tumors.

The EMA’s CHMP has recommended the approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors.

CHMP recommended ibrutinib plus immunochemotherapy for previously untreated, transplant-eligible mantle cell lymphoma.

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.

Pembrolizumab plus chemoradiation with maintenance pembrolizumab was safe and effective in unresectable vulvar cancer.

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

BGB-16673 was safe and effective for the treatment of patients with relapsed/refractory Waldenström Macroglobulinemia.

Cancer center's Chief Strategy Officer and Chair of Thoracic Surgery joins prestigious organization

Martin E. Gutierrez, MD, discusses steps towards a continuous shift in both the NSCLC and SCLC treatment paradigms, based on trials presented at ASCO 2025.

Galleri, a multicancer early detection test, demonstrated high positive predictive value and cancer detection in PATHFINDER 2.

Adjuvant ribociclib plus endocrine therapy has gained Canadian approval for HR-positive/HER2-negative early breast cancer at high risk of recurrence.

Evan S. Wu, MD, PhD, delves into the one of the most pivotal aspects of designing a successful bridging study: the selection of clinical end points.

Kevin Kalinsky, MD, MS, FASCO, discusses how findings from SERENA-6 reinforce the importance of timely ESR1 testing in HR-positive breast cancer.

Joshua K. Sabari, MD, discusses the role of telisotuzumab vedotin in patients with locally advanced/metastatic NSCLC with c-MET overexpression.

Sarah Sammons, MD, discusses data with T-DXd in frontline HER2-positive breast cancer and other ADCs in the breast cancer space.

The FDA approved tafasitamab-cxix plus lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma.

Venetoclax plus rituximab displayed OS and PFS benefits vs BR after long-term follow-up in relapsed/refractory CLL.

Mazyar Shadman, MD, MPH, discusses key efficacy and safety findings from arm D of the SEQUOIA trial of first-line zanubrutinib plus venetoclax in CLL/SLL.

SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.

Atebimetinib plus gemcitabine/nab-paclitaxel produced signals of survival benefits in first-line pancreatic cancer.

Jessica Paulus, ScD, highlights factors that may contribute to the increasing incidence of colorectal cancer in patients younger than 50 years of age.

Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.

Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.

Imetelstat demonstrated clinical benefits in patients with ring sideroblast–negative lower-risk MDS, according to a post hoc analysis.

The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.